NFC-1
NFC1-2014
Phase 1 small_molecule completed
Quick answer
NFC-1 for Attention-deficit Hyperactivity Disorder (ADHD) is a Phase 1 program (small_molecule) at Avalo Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Avalo Therapeutics
- Indication
- Attention-deficit Hyperactivity Disorder (ADHD)
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed